by Raynovich Rod | Nov 28, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Macro
Uncertainty Grips Markets- But December Still Looks Good Major Indices are down as of 11 am trading amid protest in China.Apple (AAPL) is down over 2% on potential production shortfall from Foxconn.The XBI is flat at thee $81 level but large caps are strong and the...
by Raynovich Rod | Sep 5, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Macro
9/12/22…Bristol-Myers (BMY) up 5% on FDA approval of psoriasis drug.Large cap biopharmas rally: AZN, GILD, MRK, etc. Mid- caps green esp MDGL,MRTX. Morgan Stanley Healthcare conference was today could account for biotech strength. Biden Issues Executive Order on...
by Raynovich Rod | Aug 28, 2022 | 2020-21 Life Science Portfolios, Macro
Update-1 Third Day this week of flailing around in the red, even AAPL down 1%. Small cap winners: EVH,MRTX, QDEL speculative ETFs: ARKG up 1.31%, XBI up 0.72% at $83.70 IBB flat at $121.46, XLV down 0.64% at $124.76. Notable biotech movers: CYTK up 3.78% at $52.96,...
by Raynovich Rod | Jun 27, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
Update-3 July 5 11a EDT Rally in speculative biotech stocks with XBI up1.85% to $77 handle. Early movers: AGEN, CRSP, CYRX, DNA, QDEL, ROIV, VCYT all on our focus list. Added to Moderna (MRNA) at $153. Market indices in red on recession fears with S%P 500 down 1.9%...
by Raynovich Rod | Jun 21, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 June 22…Market ends trading day flattish with usual choppiness focused on macro after Powell speaks. Recession fears dominate with energy stocks down again. Bright spot is healthcare sector led by large caps with nibbling in beaten- up small caps. Like...
by Raynovich Rod | Jun 13, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 6/20 10:30p PDT…. Futures are up poised for a nice rally tomorrow. Last week even healthcare stocks hit new YTD lows with the XLV down 14.91% YTD now at $119.89. Even large cap biopharma stocks have sold off over the past month. ==== Update-1 FED raises...
by Raynovich Rod | May 30, 2022 | 2020-21 Life Science Portfolios, 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Healthcare stocks, Macro
Update-4 June 8 Sideways market with trading opportunities in Small cap biotechs. With markets so choppy day to day and volatile within day it is hard to trade. But in my most recent trades I am more hopeful with this buying window. The bellwether remains XBI which...
by Raynovich Rod | May 8, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Macro
Update-2 …5/13 Many analysts see today’s sharp upside action as an oversold rally from 2022 lows.The highest risk stocks soared along with large cap tech stocks. NASDAQ was up 3.75%,S&P up 2.3%, DOW up 1.42%. To some extent this shifted action away...
by Raynovich Rod | Feb 8, 2022 | 2021 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Macro
At close 2/11: Another crappy day now with Ukraine Crisis coming to fore. But some large cap biopharmas get green: BMY. GILD, REGN up 3.27%, and PFE. Nibbled on NeuroCrine (NBIX) at $85. Update-3 2/11 12p EST…Small caps fight the headwinds but “hold the...
